Noxafil Tablet, Coated
Product Images NDC 0085-4324

Product Visual Gallery

This gallery contains 44 technical images submitted to the FDA as part of the official labeling for Noxafil (NDC 0085-4324). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Merck Sharp & Dohme Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Noxafil 01)

An instructional illustration of a dosing spoon with measurement indicators for 2.5 mL and 5 mL volumes, intended for oral administration of medication.*

FDA Label Image

Chemical Structure (Noxafil 02)

Chemical structure of posaconazole, the active ingredient in NOXAFIL oral powder suspension. The diagram shows the molecular structure with multiple aromatic rings and fluorine atoms.*

FDA Label Image

Figure A (Noxafil 02a)

An illustration of a dosing spoon with volume markings at 2.5 mL and 5 mL, used for measuring oral suspension doses. The spoon is designed to assist in accurate liquid medication dosing.*

FDA Label Image

Principal Display Panel (105 mL Bottle Carton)

Carton label for NOXAFIL oral suspension 200 mg/5 mL (posaconazole) powder for suspension, 105 mL. The label includes preparation instructions, storage conditions, and manufacturer details for Merck Sharp & Dohme Corp. The carton notes to shake well before use and that it contains a measured dosing spoon, with usage instructions and dosage caution.*

FDA Label Image

Principal Display Panel (60 Tablet Bottle Label)

Noxafil (posaconazole) delayed-release tablets 100 mg label. The label specifies 100 mg strength, indicates 60 tablets per package, and states the product is prescription only (Rx only). The label includes storage instructions and a tablet image embossed with '100'. Manufacturer is Merck Sharp & Dohme LLC.*

FDA Label Image

Principal Display Panel (16.7 mL Vial Carton)

Noxafil (posaconazole) Injection 300 mg/16.7 mL (18 mg/mL) carton label for intravenous use only. The label includes product strength, usage instructions indicating it requires further dilution prior to infusion, storage conditions, inactive ingredients, manufacturer information (Merck Sharp & Dohme Corp.), and barcode. It is a sterile single-dose vial with Rx only status, advising to discard unused portion.*

FDA Label Image

Figure (Noxafil 06)

FDA Label Image

Figure (Noxafil 07)

An instructional diagram showing three views of NOXAFIL oral powder for suspension packaging: a carton, a foil packet, and a suspension bottle, each with callouts highlighting specific label details on the packaging and product components.*

FDA Label Image

Figure (Noxafil 08)

NOXAFIL 300 mg/1 oral powder for suspension carton, showing the product name, dosage strength 300 mg/1, and manufacturer Merck Sharp & Dohme LLC. The packaging is primarily white with yellow and gray accents and includes product identification and labeling information on multiple sides.*

FDA Label Image

Figure (Noxafil 09)

Diagram of two dosing cups representing the measurement of NOXAFIL oral suspension. The image shows graduated markings inside the cups, typically used for accurately measuring oral liquid medication doses.*

FDA Label Image

Figure (Noxafil 10)

NOXAFIL posaconazole oral powder for suspension carton. The packaging is primarily white with a simple rectangular shape and a flap opening on the top. No visible text other than the general appearance of a folded box is shown.*

FDA Label Image

Figure (Noxafil 11)

NOXAFIL posaconazole powder for suspension packets, shown as a set of individually packaged single-dose sachets. The packaging indicates oral route and prescription drug status, manufactured by Merck Sharp & Dohme LLC. Specific strengths and quantities are not visible in the image.*

FDA Label Image

Figure (Noxafil 12)

An instructional or anatomical diagram depicting a segmented, ringed structure. The image appears to be a simplified line drawing, possibly showing a component related to the product's administration or packaging mechanism, without any text or dosage information.*

FDA Label Image

Figure (Noxafil 13)

NOXAFIL Mixing Liquid bottle label for posaconazole oral suspension, a human prescription drug by Merck Sharp & Dohme LLC. The label indicates this is a mixing liquid for posaconazole delayed-release oral suspension, supplied in a bottle containing 473 mL (1 pint). Usage and storage instructions are also visible on the label.*

FDA Label Image

Figure (Noxafil 14)

Two blue oral dosing syringes for NOXAFIL (posaconazole) powder for suspension. Syringes are designed for measuring and administering the liquid suspension form of NOXAFIL, a prescription antifungal medication by Merck Sharp & Dohme LLC.*

FDA Label Image

Figure (Noxafil 15)

Noxafil oral powder for suspension, shown as two green- and transparent-colored syringes designed for oral dosing. The product is posaconazole by Merck Sharp & Dohme LLC, available in strengths 100 mg/1 and 300 mg/1 among others. The image highlights the dosing delivery form with graduated markings on the syringes.*

FDA Label Image

Figure (Noxafil 16)

An instructional illustration showing a plastic oral dosing syringe with labeled parts: plunger, clear plastic barrel, measuring scale, and notched tip. The image highlights the syringe's components used for measuring and administering liquid medication.*

FDA Label Image

Figure (Noxafil 17)

Illustration showing a hand removing a child-resistant cap from a glass medication bottle. The image depicts a close-up view of the cap being lifted off the bottle neck, likely indicating how to open the bottle containing an oral suspension.*

FDA Label Image

Figure (Noxafil 18)

An instructional illustration showing a hand opening a bottle labeled "Mixing Liquid," with an arrow indicating the direction to twist or remove the bottle cap. The image is related to preparing NOXAFIL oral powder for suspension.*

FDA Label Image

Figure (Noxafil 19)

An instructional illustration showing a hand holding a bottle and twisting or opening its cap, with lines indicating the motion to mix the liquid contained within. The label on the bottle partially reads 'MIXING LIQUID.'*

FDA Label Image

Figure (Noxafil 20)

An instructional illustration showing a container with a hinged lid that opens by lifting a tab. The diagram demonstrates the correct way to open the lid of the container, likely for NOXAFIL oral suspension powder.*

FDA Label Image

Figure (Noxafil 21)

NOXAFIL oral powder for suspension 100 mg packet by Merck Sharp & Dohme LLC. The image shows a single-dose foil packet labeled NOXAFIL with posaconazole as the active ingredient, dosed at 100 mg per packet, intended for oral suspension preparation.*

FDA Label Image

Figure (Noxafil 22)

NOXAFIL mixing liquid bottle label for posaconazole oral suspension. The label shows instructions to mix the powder with a specified liquid to prepare posaconazole suspension, specifying an orange-cream flavor. The net content is 473 mL. The product is labeled by Merck Sharp & Dohme LLC.*

FDA Label Image

Figure (Noxafil 23)

NOXAFIL oral powder for suspension packaging label showing two cylindrical bottles or vials. The larger container has a blue label with volume measurement marks visible, and the smaller container has a green label with similar volume markings. No additional text or dosage details are visible on the image.*

FDA Label Image

Figure (Noxafil 24)

FDA Label Image

Figure (Noxafil 25)

An instructional diagram showing the packaging and preparation steps for NOXAFIL oral suspension powder. The image highlights the opened carton and a zoomed-in view emphasizing the bottle cap and internal components, likely illustrating how to access or prepare the suspension.*

FDA Label Image

Figure (Noxafil 26)

An instructional illustration showing a hand holding a sachet, shaking it to mix or prepare the contents. A pair of scissors is shown on a nearby surface, indicating the sachet may need to be cut open. No text is visible in the image.*

FDA Label Image

Figure (Noxafil 27)

An instructional illustration showing a step in medication preparation: two hands holding a packet above a container, with an arrow indicating the packet's contents being poured into the container. This likely depicts mixing or adding powder to a liquid for suspension preparation.*

FDA Label Image

Figure (Noxafil 28)

An instructional illustration showing a hand holding and shaking a bottle of NOXAFIL posaconazole oral suspension powder reconstituted into liquid form. The image demonstrates proper mixing technique by shaking the bottle before use.*

FDA Label Image

Figure (Noxafil 29)

An instructional illustration showing a hand holding a bottle dispensing liquid medicine into a syringe marked with a 9 mL scale. The syringe parts are labeled: Tip, Barrel, 9 mL, and Plunger, highlighting proper usage for measuring oral suspension.*

FDA Label Image

Figure (Noxafil 30)

An instructional illustration showing a hand holding a syringe containing blue liquid. A zoomed inset highlights the syringe's volume markings from 1 mL to 3 mL and points out the presence of air bubbles within the liquid. The image appears to guide proper measurement or preparation steps for oral administration.*

FDA Label Image

Figure (Noxafil 31)

An instructional diagram showing how to measure oral suspension using a syringe. The syringe is marked with volume lines, and a zoomed inset highlights the liquid level between 8 mL and 10 mL as the person prepares to draw or dispense medication orally.*

FDA Label Image

Figure (Noxafil 32)

An instructional line drawing showing hands preparing oral suspension medication. One hand holds an open container with powder inside, while the other hand inserts a syringe into the container. A green arrow points downward toward the container, indicating the action of drawing or mixing the medication.*

FDA Label Image

Figure (Noxafil 33)

An instructional illustration showing a hand shaking a small container of suspension with a stopwatch indicating 45 seconds. The image demonstrates the importance of shaking the container for 45 seconds before use.*

FDA Label Image

Figure (Noxafil 34)

An illustration showing a person looking at a small container or vial from the side. The image likely depicts how to visually inspect the contents of an oral suspension product container.*

FDA Label Image

Figure (Noxafil 35)

An instructional diagram showing a person inhaling or sniffing medication from an open NOXAFIL powder for suspension carton. The carton is illustrated with the label visible, indicating the product and its usage form.*

FDA Label Image

Figure (Noxafil 36)

An illustration of a green oral dosing syringe, marked with volume measurements from 0.5 mL to 3 mL in 0.5 mL increments.*

FDA Label Image

Figure (Noxafil 37)

An illustration of a clear oral dosing syringe marked with volume measurements from 1 mL to 10 mL in 1 mL increments, showing a blue stopper at the top and a nozzle at the bottom for administering liquid medication. No branding or additional text is visible.*

FDA Label Image

Figure (Noxafil 38)

An instructional diagram showing how to prepare and measure oral suspension medication using a dosing syringe and a measuring spoon. The image includes a hand handling the medication packaging, opening blister packs with capsules or tablets, and filling the syringe with liquid from a spoon.*

FDA Label Image

Figure (Noxafil 39)

An instructional diagram showing how to hold and prepare an oral syringe with measurement markings from 1 to 3 mL, highlighting air gaps and air bubbles within the syringe. The illustration focuses on proper syringe handling technique for administering a suspension medication.*

FDA Label Image

Figure (Noxafil 40)

Instructional illustration showing a profile of a person holding an oral dosing syringe vertically and pulling the plunger upward, with drops of liquid coming out the tip, indicating how to draw or measure liquid medication accurately for oral administration.*

FDA Label Image

Figure (Noxafil 41)

Instructional illustration showing a child receiving an oral dose of suspension medication using a syringe held by a caregiver. The image depicts proper administration technique by placing the syringe into the child's mouth.*

FDA Label Image

Figure (Noxafil 42)

An instructional illustration showing two steps for cleaning a medication dosing syringe. The first step depicts disposing of liquid into a trash container with a foot pedal opener. The second step shows rinsing the syringe under running water in a sink.*

FDA Label Image

Principal Display Panel (300 mg Carton)

Noxafil PowderMix 300 mg for Delayed-Release Oral Suspension packaging label. Contains posaconazole as the active ingredient. The multi-dose kit includes 8 packets of 300 mg each, mixing liquid, and syringes. Labels display storage instructions, dosage recommendations, manufacturer details (Merck Sharp & Dohme LLC), and a pharmacy label area.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.